{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:47:43Z","timestamp":1793029663882,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013099","name":"Scientific Research Fund of Liaoning Provincial Education Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ejphar.2024.176952","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T06:45:52Z","timestamp":1725000352000},"page":"176952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"983","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-2906","authenticated-orcid":false,"given":"Yingshi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhai","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hefeng","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanghua","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengkang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanbo","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aigang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.176952_bib1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/14740338.2023.2218085","article-title":"The efficacy and safety of Capivasertib (AZD5363) in the treatment of patients with solid tumor: a systematic review and meta-analysis of randomized clinical trials","volume":"22","author":"Abushanab","year":"2023","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejphar.2024.176952_bib2","article-title":"PIK3CA copy-number gain and inhibitors of the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer","volume":"9","author":"Amato","year":"2023","journal-title":"Cold Spring Harbor molecular case studies"},{"key":"10.1016\/j.ejphar.2024.176952_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann. Oncol. : Off. J. European Soc. Med. Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib4","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.176952_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ejphar.2024.176952_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.11.017","article-title":"A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer","volume":"108","author":"Bang","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2024.176952_bib7","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-21-3045","article-title":"Phase 1b clinical trial with alpelisib plus olaparib for patients with advanced triple-negative breast cancer","volume":"28","author":"Batalini","year":"2022","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ejphar.2024.176952_bib8","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41416-023-02221-1","article-title":"The emerging role of PI3K inhibitors for solid tumour treatment and beyond","volume":"128","author":"Belli","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2024.176952_bib9","doi-asserted-by":"crossref","first-page":"e1604","DOI":"10.1634\/theoncologist.2020-0321","article-title":"A phase ib study of single-agent idelalisib followed by idelalisib in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"25","author":"Borazanci","year":"2020","journal-title":"Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.medcli.2022.01.011","article-title":"Colitis due to idelalisib in a patient with follicular lymphoma. Colitis por idelalisib en un paciente con linfoma folicular","volume":"159","author":"Canelo-Vilaseca","year":"2022","journal-title":"Med. Cl\u00ednica"},{"issue":"10","key":"10.1016\/j.ejphar.2024.176952_bib11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.19.01027","article-title":"MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2-positive and\/or hormone receptor-negative breast cancers in the I-spy 2 trial","volume":"38","author":"Chien","year":"2020","journal-title":"J. Clin. Oncol. : Off. J. American Soc. Clinic. Oncol."},{"issue":"4","key":"10.1016\/j.ejphar.2024.176952_bib12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaoncol.2016.5383","article-title":"Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial","volume":"3","author":"Chung","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib13","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.20.01139","article-title":"Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer from SOLAR-1","volume":"39","author":"Ciruelos","year":"2021","journal-title":"J. Clin. Oncol. : Off. J. American Soc. Clinic. Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib14","unstructured":"Clinical Trials. gov Identifier: NCT01485861 Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT01485861?intr=Ipatasertib\/20&page=3&tab=results&rank=29#outcome-measures."},{"key":"10.1016\/j.ejphar.2024.176952_bib15","unstructured":"Clinical Trials. gov Identifier: NCT01732913 Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01732913?cond=NCT01732913&draw=2&rank=1."},{"key":"10.1016\/j.ejphar.2024.176952_bib16","unstructured":"Clinical Trials. gov Identifier: NCT01732926 Available at: https:\/\/clinicaltrials.gov\/study\/NCT01732926?cond=NCT01732926&rank=1."},{"key":"10.1016\/j.ejphar.2024.176952_bib17","unstructured":"Clinical Trials. gov Identifier: NCT01980875 Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/results\/NCT01980875?cond=NCT01980875&draw=2&rank=1."},{"key":"10.1016\/j.ejphar.2024.176952_bib18","unstructured":"Clinical Trials. gov Identifier: NCT02049515 Available at: https:\/\/clinicaltrials.gov\/study\/NCT02049515?intr=NCT02049515&rank=1."},{"key":"10.1016\/j.ejphar.2024.176952_bib19","unstructured":"Clinical Trials. gov Identifier: NCT02204982 Available at: https:\/\/clinicaltrials.gov\/study\/NCT02204982?intr=NCT02204982&rank=1."},{"key":"10.1016\/j.ejphar.2024.176952_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2022.05.019","article-title":"Overall survival update for patients with metastatic castration-resistant prostate cancer treated with capivasertib and docetaxel in the phase 2 ProCAID clinical trial","volume":"82","author":"Crabb","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2024.176952_bib21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.20.01576","article-title":"Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase II trial (ProCAID)","volume":"39","author":"Crabb","year":"2021","journal-title":"J. Clin. Oncol. : Off. J. American Soc. Clinic. Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40264-018-0778-4","article-title":"Safety and tolerability of phosphatidylinositol-3-kinase (PI3K) inhibitors in Oncology","volume":"42","author":"Curigliano","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2024.176952_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/17474086.2023.2192918","article-title":"Current therapies for chronic lymphocytic leukemia: risk and prophylaxis strategies for secondary\/opportunistic infections","volume":"16","author":"Diella","year":"2023","journal-title":"Expet Rev. Hematol."},{"key":"10.1016\/j.ejphar.2024.176952_bib24","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2024.176952_bib25","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"A dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J. Clin. Oncol. : Off. J. American Soc. Clinic. Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.176952_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2024.176952_bib28","doi-asserted-by":"crossref","first-page":"E52","DOI":"10.1002\/ajh.24981","article-title":"Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: a retrospective study of the French innovative leukemia organization (FILO)","volume":"93","author":"Godet","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2024.176952_bib29","article-title":"Mortality due to cancer treatment delay: systematic review and meta-analysis","volume":"371","author":"Hanna","year":"2020","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2024.176952_bib30","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2024.176952_bib31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.ejphar.2024.176952_bib32","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1470-2045(22)00284-4","volume":"23","author":"Howell","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.887332","article-title":"What is the most suitable agent combined with apatinib for transarterial chemoembolization treatment in advanced hepatocellular carcinoma patients? A systematic review and network meta-analysis","volume":"12","author":"Hui","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.ejphar.2024.176952_bib34","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdw676","article-title":"A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma","volume":"28","author":"Jonasch","year":"2017","journal-title":"Ann. Oncol. : Off. J. European Soc. Med. Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib35","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.ejphar.2024.176952_bib36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(19)30817-4","article-title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial","volume":"21","author":"Jones","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.22.02786","article-title":"Personalized biomarker-based umbrella trial for patients with recurrent or metastatic head and neck squamous cell carcinoma: KCSG HN 15-16 TRIUMPH trial","volume":"42","author":"Keam","year":"2024","journal-title":"J. Clin. Oncol. : Off. J. American Soc. Clinic. Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib38","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"LOTUS investigators. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/14740338.2021.1931116","article-title":"Efficacy and safety of CDK4\/6 and PI3K\/AKT\/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis","volume":"20","author":"Leung","year":"2021","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejphar.2024.176952_bib40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2147\/DDDT.S242521","article-title":"Hydrogen sulfide protects against high glucose-induced human umbilical vein endothelial cell injury through activating PI3K\/Akt\/eNOS pathway","volume":"14","author":"Lin","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2024.176952_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113729","article-title":"PI3K\/AKT\/mTOR signaling as a molecular target in head and neck cancer","volume":"172","author":"Marquard","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176952_bib42","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1470-2045(21)00145-5","article-title":"Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Matasar","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clgc.2023.01.001","article-title":"Safety profile of ipatasertib plus abiraterone vs placebo plus abiraterone in metastatic castration-resistant prostate cancer","volume":"21","author":"Matsubara","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.ejphar.2024.176952_bib44","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1158\/1078-0432.CCR-18-3160","article-title":"A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NEO-ORB)","volume":"25","author":"Mayer","year":"2019","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ejphar.2024.176952_bib45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12955-019-1232-8","article-title":"Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine\/rituximab-treated patients: results of a phase 3, randomized, controlled trial","volume":"17","author":"Montillo","year":"2019","journal-title":"Health Qual. Life Outcome"},{"key":"10.1016\/j.ejphar.2024.176952_bib46","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/annonc\/mdz177","article-title":"FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer","volume":"30","author":"Oliveira","year":"2019","journal-title":"Ann. Oncol. : Off. J. European Soc. Med. Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib47","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2024.176952_bib48","first-page":"7667","article-title":"Efficacy and safety of PI3K\/Akt\/mTOR inhibitors combined with trastuzumab therapy for HER2-positive breast cancer: a meta-analysis","volume":"26","author":"Peng","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2024.176952_bib49","series-title":"Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care (Internet)","year":"2009"},{"key":"10.1016\/j.ejphar.2024.176952_bib50","doi-asserted-by":"crossref","first-page":"E183","DOI":"10.1002\/ajh.25480","article-title":"Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group","volume":"94","author":"Quinquenel","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2024.176952_bib51","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s11523-023-00997-z","article-title":"A phase 1b\/2 study of alpelisib in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma","volume":"18","author":"Razak","year":"2023","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114103","article-title":"Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: results from the randomized phase II RE-AKT trial","volume":"205","author":"Rescigno","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2024.176952_bib53","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","article-title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer","volume":"31","author":"Rugo","year":"2020","journal-title":"Ann. Oncol. : Off. J. European Soc. Med. Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib54","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J. Clin. Oncol. : Off. J. American Soc. Clinic. Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib55","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1158\/1078-0432.CCR-23-2084","article-title":"First-line ipatasertib, atezolizumab, and taxane triplet for metastatic triple-negative breast cancer: clinical and biomarker results","volume":"30","author":"Schmid","year":"2024","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"11","key":"10.1016\/j.ejphar.2024.176952_bib56","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2024.176952_bib57","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J. Clin. Oncol. : Off. J. American Soc. Clinic. Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib58","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.clgc.2022.11.017","article-title":"A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer","volume":"21","author":"Shore","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.ejphar.2024.176952_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107966","article-title":"Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials","volume":"230","author":"Song","year":"2022","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2024.176952_bib60","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1080\/10428194.2021.1964020","article-title":"Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor","volume":"62","author":"Staber","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"2021","key":"10.1016\/j.ejphar.2024.176952_bib61","article-title":"Growth factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now?","volume":"22","author":"Stefani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176952_bib62","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2024.176952_bib63","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejphar.2024.176952_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","article-title":"Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy","volume":"80","author":"Tewari","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejphar.2024.176952_bib65","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2024.176952_bib66","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10549-021-06450-x","article-title":"Ipatasertib plus paclitaxel for PIK3CA\/AKT1\/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial","volume":"191","author":"Turner","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2024.176952_bib67","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2021.07.008","article-title":"The effectiveness of monotherapy with PI3K\/AKT\/mTOR pathway inhibitors in ovarian cancer: a meta-analysis","volume":"163","author":"van der Ploeg","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib68","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1080\/10428194.2021.1948038","article-title":"Idelalisib immune-related toxicity is associated with improved treatment response","volume":"62","author":"Wagner-Johnston","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejphar.2024.176952_bib69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.apsb.2021.07.023","article-title":"Targeting PI3K\/AKT signaling for treatment of idiopathic pulmonary fibrosis","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejphar.2024.176952_bib70","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s11864-022-00953-5","article-title":"Chronic lymphocytic leukemia: chemotherapy free and other novel therapies including CAR T","volume":"23","author":"Wiedmeier-Nutor","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments","volume":"14","author":"WLo","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ejphar.2024.176952_bib72","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12967-022-03337-3","article-title":"Study effect of probiotics and prebiotics on treatment of OVA-LPS-induced of allergic asthma inflammation and pneumonia by regulating the TLR4\/NF-kB signaling pathway","volume":"20","author":"Wu","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejphar.2024.176952_bib73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12894-023-01389-1","article-title":"Incidence of renal cell carcinoma after solid organ transplantation: a systematic review and meta-analysis","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Urol."},{"key":"10.1016\/j.ejphar.2024.176952_bib75","article-title":"Could camrelizumab plus chemotherapy improve clinical outcomes in advanced malignancy? A systematic review and network meta-analysis","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib76","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3390\/nu15092023","article-title":"HMC ameliorates hyperglycemia via acting PI3K\/AKT pathway and improving FOXO1 pathway in ob\/ob mice","volume":"15","author":"Yoo","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.ejphar.2024.176952_bib77","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejphar.2024.176952_bib78","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12964-022-00951-y","article-title":"The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors","volume":"20","author":"Zalpoor","year":"2022","journal-title":"Cell Commun. Signal. : CCS"},{"key":"10.1016\/j.ejphar.2024.176952_bib79","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2024.176952_bib80","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2217\/fon-2022-1220","article-title":"Addition of PI3K\/AKT\/mTOR inhibitors to fulvestrant for advanced HR+\/HER2- breast cancer: a systematic review and meta-analysis","volume":"19","author":"Zhang","year":"2023","journal-title":"Future Oncol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924006411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924006411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:50:14Z","timestamp":1730436614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924006411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":79,"alternative-id":["S0014299924006411"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176952","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"176952"}}